ClinicalTrials.gg
RecruitingNCT06071858Updated Feb 27, 2026

Enhanced Coordinated Specialty Care for Early Psychosis

An interventional study of Care Coordination and Individual Peer Support in Psychosis, Schizophrenia and Schizoaffective Disorder, sponsored by Mclean Hospital. Recruiting at 5 sites in United States. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Mclean Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
350
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Psychotic Disorders by Mclean Hospital — 6 open to participants now, 6 under way, none of them phase 3. Psychotic Disorders · Mclean Hospital.

Planned enrollment
Largest of 17
350 · median 50
Started
2024
with 3 others
No phase
11 of 18
6 open now
Registered
14th of 18
by date

Among the 18 studies in Psychotic Disorders by Mclean Hospital, this one has the largest planned enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2024, is one of 11 with no phase, and was the 14th registered.

Psychotic Disorders

1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

6 of the 18 studies in Psychotic Disorders by Mclean Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Psychotic Disorders by Mclean Hospital, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare engagement in treatment in coordinated specialty care (CSC) to five extra care elements (CSC 2.0) in first-episode psychosis. The main question it aims to answer is:

  • Does the addition of certain elements of care increase the number of visits in treatment for first-episode psychosis?

Participants will either:

  • Receive care as usual (CSC) or
  • Receive care as usual (CSC) plus five additional care elements (CSC 2.0):

    1. Individual peer support
    2. Digital outreach
    3. Care coordination
    4. Multi-family group therapy
    5. Cognitive remediation

Researchers will compare the standard of care (CSC) to CSC 2.0 to see if participants receiving CSC 2.0 have more visits to their clinic in their first year.

03

Conditions studied

  • Psychosis
  • Schizophrenia
  • Schizoaffective Disorder
  • Psychosis Nos/Other
  • Bipolar Disorder

Keywords

  • first episode psychosis
  • early psychosis
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • People undergoing an intake evaluation to CSC for first-episode psychosis in one of the following outpatient clinics:
  • McLean Hospital OnTrack (OnTrack Clinic)
  • Massachusetts General Hospital (FEPP Clinic)
  • Boston Medical Center (WRAP Clinic)
  • Cambridge Health Alliance (RISE Clinic)
  • UMass Memorial Health Care (STEP Clinic)
  • ServiceNet (PREP West)

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
350 participants (estimated)

Study arms

  • No intervention
    Coordinated Specialty Care (CSC; standard of care)

    Care as usual; no intervention.

  • Experimental
    Enhanced Coordinated Speciality Care (CSC 2.0)

    CSC 2.0 arm will be offered 1:1 peer support, digital outreach, care coordination, multi-family group therapy, and cognitive remediation (if applicable).

    Behavioral: Care Coordination · Behavioral: Individual Peer Support · Behavioral: Digital Outreach · Behavioral: Cognitive Remediation · Behavioral: Multi-Family Group Therapy

Interventions

  • BehavioralCare Coordination

    * The study staff clinician will review all medical issues for each patient and reach out to primary care providers (PCP), dieticians, and other medical providers as needed. * The study staff clinician will serve as point person for communication with emergency departments and inpatient providers if the patient requires those levels of care. * The clinician will communicate with outside providers to provide background and ensure health decision making by those providers, visit and support patients as appropriate, access outside records and share with rest of the care team, and most critically ensure that a proper discharge plan has been made for the patient including care appointments, access to prescriptions and any new referrals made during hospitalization.

  • BehavioralIndividual Peer Support

    • Patients will be offered weekly 1:1 sessions with a Peer Provider as part of routine care in a mixture of in-person and virtual formats as appropriate to support patients around treatment decisions, and recovery.

  • BehavioralDigital Outreach

    • mindLAMP smartphone application for various kinds of outreach including but not limited to medication and/or appointment reminders, resources, and activities such as breathing and meditation exercises.

  • BehavioralCognitive Remediation

    * For participants identified as needing and/or wanting support around cognition. * The cognitive remediation program is available online or in-app and offers memory, attention, processing speed, executive functioning, and social cognition training activities.

  • BehavioralMulti-Family Group Therapy

    * Families whose loved ones are in CSC clinic will be offered weekly group sessions with a study staff clinician. * Each group may include 5-8 families and include a mixture of in-person and virtual formats. * These groups will be open-ended, including psychoeducation, and practical problem-solving discussions around care and other topics.

06

What researchers measure

Primary outcomes

  1. Months Engaged in Care

    Number of months each participant had ≥4 visits in a 12-month period

    Time frame: 12 months following clinic intake

Secondary outcomes

  1. Clinic Visit Number

    Total number of clinic visits in a 12-month period

    Time frame: 12 months following clinic intake

  2. Clinic Visit Type

    Numbers of different types of visits (eer provider, psychotherapy, psychopharmacology, group therapy, etc.) in a 12-month period

    Time frame: 12 months following clinic intake

  3. Duration of Treatment

    Duration of time in treatment

    Time frame: Up to 12 months - measured as time between clinic intake and detachment

  4. Proportion in Arm Still in Clinic

    Proportion of patients in each arm who are still in CSC at the end of the 12-month follow-up period

    Time frame: 12 months following clinic intake

Other outcomes

  1. Exploratory Analysis of symptom and functioning measures in EPINET Core Assessment Battery (CAB)

    Exploratory analysis of variables collected by EPINET CAB by arm

    Time frame: 12 months following clinic intake

  2. Proportion of Early Detachment

    Proportion of patients in each arm who detach from clinic prior to the end of their first month in care

    Time frame: 1 month

  3. Months Engaged in Care - extension of primary outcome

    Number of months each participant had ≥4 visits in a 24-month period

    Time frame: 24 months

07

Study locations

5 of 5 sites recruiting
  • McLean Hospital OnTrack Clinic
    Belmont, Massachusetts 02478, United States
    Recruiting
    • Dost Ongur, MD, PhD · Contact
  • Massachusetts General Hospital FEPP Clinic
    Boston, Massachusetts 02114, United States
    Recruiting
    • Dost Ongur, MD, PhD · Contact
  • Boston Medical Center WRAP
    Boston, Massachusetts 02118, United States
    Recruiting
    • Dost Ongur, MD, PhD · Contact
  • Cambridge Health Alliance RISE Clinic
    Cambridge, Massachusetts 02139, United States
    Recruiting
    • Dost Ongur, MD, PhD · Contact
  • UMass Memorial Community Healthlink STEP Clinic
    Worcester, Massachusetts 01610, United States
    Recruiting
    • Dost Ongur, MD, PhD · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Oct 2028, 56 months after the start.

Of 460 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 56 months is above that.

Counting every sponsor, half of 462 studies reached it within 34 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2023
First posted
Oct 10, 2023
StartActual
Feb 1, 2024
Primary completionEst.
Oct 2028
CompletionEst.
Oct 2028
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06071858
Lead sponsor
Mclean Hospital
Responsible party
Dost Ongur (Director, LEAP Center, Mclean Hospital) — Principal investigator
First posted
Oct 10, 2023
Start date
Feb 1, 2024
Primary completion
Oct 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Feb 27, 2026

Study contacts

Dost Ongur, MD, PhD
Contact
dongur@mgb.org
617-855-3922
Jacqueline Dow, MPH
Contact
jdow@mclean.harvard.edu
617-855-3321
Dost Ongur, MD, PhD
principal investigator · Mclean Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion